Celsis announces more growth for full-year 08

Celsis International, a UK-based life science and laboratory services company, has announced its sixth year with over 10% profit growth.

For the year ending March 31, 2008, the firm reported sales of $56.1 million, up 18% versus $47.4 million posted for the same period the year before. Profit before tax was also up, rising 16% to $10.0 million vs $8.7 million for full-year 2007. This resulted in earnings per share of $0.31 vs $0.27, a 14% difference.

The firm's Rapid Detection revenues were up 23% to $21.7 million vs just $17.7 million, which the company attributes to strong growth in instrument placements and notes a new RNA-based system will be launched next year. In vitro technologies sales were also up, 15%, to $15.4 million vs $13.3 million, pro-rated for the 12-month period of 2007. Analytical Services turnover, however, decreased 7.1% to $19.0 million, vs $20.4 million for the year before, which the firm blamed on a "tough comparator year." Jay LeCoque, Celsis' chief executive, said the year had been "highly successful," and looked forward to the next period.